기본 통계
| CIK | 1819576 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Liquidia Corporation
SEC Filings (Chronological Order)
이 페이지는 다른 곳에서 제공하는 소유권 보고서를 제외한 SEC 보고서의 전체 리스트를 시간 순으로 정리한 것입니다.
| May 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001 |
|
| May 11, 2026 |
Exhibit 99.2 ©2026 LIQUIDIA CORPORATION ALL RIGHTS RESERVED First Quarter 2026 Earnings & Corporate Update Liquidia Corporation May 11, 2026 2 ©2026 LIQUIDIA CORPORATION ALL RIGHTS RESERVED Forward - looking statements This presentation may include forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . All statements contained in this presentation |
|
| May 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2026 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File |
|
| May 11, 2026 |
Liquidia Corporation Reports First Quarter 2026 Financial Results Exhibit 99.1 Liquidia Corporation Reports First Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $130 million in the first quarter of 2026 · More than 4,500 unique patient prescriptions and approximately 3,750 patients treated between launch in June 2025 and April 30, 2026 · Recorded third consecutive quarter of profitability, with net |
|
| April 24, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10 - K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001 - 39724 LIQUIDIA CORPORATION |
|
| April 24, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 24, 2026 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by R |
|
| March 5, 2026 |
As filed with the Securities and Exchange Commission on March 5, 2026 As filed with the Securities and Exchange Commission on March 5, 2026 Registration No. |
|
| March 5, 2026 |
As filed with the Securities and Exchange Commission on March 5, 2026 As filed with the Securities and Exchange Commission on March 5, 2026 Registration No. |
|
| March 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2026 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File |
|
| March 5, 2026 |
Exhibit 10.12 LIQUIDIA CORPORATION AMENDMENT TO STOCK OPTION AGREEMENT WHEREAS, Liquidia Corporation (the “Company”) maintains the Liquidia Corporation 2020 Long-Term Incentive Plan (the “Plan”) for the benefit of its eligible employees, officers and other individuals, including non-employee directors, who perform services for the Company or its subsidiaries; WHEREAS, the Company desires to amend |
|
| March 5, 2026 |
LIQUIDIA CORPORATION AMENDMENT TO RESTRICTED STOCK UNITS AGREEMENT Exhibit 10.14 LIQUIDIA CORPORATION AMENDMENT TO RESTRICTED STOCK UNITS AGREEMENT WHEREAS, Liquidia Corporation (the “Company”) maintains the Liquidia Corporation 2020 Long-Term Incentive Plan (the “Plan”) for the benefit of its eligible employees, officers and other individuals, including non-employee directors, who perform services for the Company or its subsidiaries; WHEREAS, the Company desires |
|
| March 5, 2026 |
LIQUIDA CORPORATION Dated as of _______________ SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE(1) Exhibit 4.3 LIQUIDA CORPORATION and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Inappli |
|
| March 5, 2026 |
Calculation of Filing Fee Tables S-3 Liquidia Corp Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Common Stock, par value $0. |
|
| March 5, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Liquidia Corp Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, par value $0. |
|
| March 5, 2026 |
EXHIBIT 21.1 Liquidia Technologies, Inc. Jurisdiction of incorporation: Delaware Name under which business conducted: Liquidia Technologies, Inc. Liquidia PAH, LLC Jurisdiction of organization: Delaware Name under which business conducted: Liquidia PAH, LLC |
|
| March 5, 2026 |
LIQUIDIA CORPORATION AMENDMENT TO RESTRICTED STOCK UNITS NOTICE (Performance Based) Exhibit 10.13 LIQUIDIA CORPORATION AMENDMENT TO RESTRICTED STOCK UNITS NOTICE (Performance Based) WHEREAS, Liquidia Corporation (the “Company”) maintains the Liquidia Corporation 2020 Long-Term Incentive Plan (the “Plan”) for the benefit of its eligible employees, officers and other individuals, including non-employee directors, who perform services for the Company or its subsidiaries; WHEREAS, th |
|
| March 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-39724 LIQUIDIA |
|
| March 5, 2026 |
Exhibit 4.4 LIQUIDA CORPORATION and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) I |
|
| March 5, 2026 |
[***] INDICATES THAT INFORMATION HAS BEEN REDACTED. Exhibit 10.55 CONFIDENTIAL EXECUTION COPY CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. LICENSE AGREEMENT dated as of October 27, 2025 by and between Vectura Limited and Liquidia Technologies, Inc. LICENSE AGREEMEN |
|
| March 5, 2026 |
LIQUIDIA CORPORATION AMENDMENT TO STOCK OPTION GRANT NOTICE Exhibit 10.11 LIQUIDIA CORPORATION AMENDMENT TO STOCK OPTION GRANT NOTICE WHEREAS, Liquidia Corporation (the “Company”) maintains the Liquidia Technologies, Inc. 2016 Equity Incentive Plan, as amended, the Liquidia Technologies, Inc. 2018 Long-Term Incentive Plan, and the Liquidia Corporation 2022 Inducement Plan (together, the “Plans”) for the benefit of its eligible service providers, who perfor |
|
| March 5, 2026 |
Exhibit 99.1 Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update · Achieved YUTREPIA® net product sales of $148.3 million for the full year 2025 with $90.1 million in the fourth quarter · More than 3,600 unique prescriptions received and 2,900 patients treated to date since launch in June 2025 · Ended 2025 with $190.7 million in cash and ca |
|
| March 5, 2026 |
As filed with the Securities and Exchange Commission on March 5, 2026 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 5, 2026 Registration Statement No. |
|
| March 5, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Liquidia Corp Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, par value $0. |
|
| January 9, 2026 |
Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update Exhibit 99.1 Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update · Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025 · Received more than 2,800 unique patient prescriptions since launch in June 2025 · Generated more than $30 million of positive cash flow during the fourth qu |
|
| January 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2026 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission F |
|
| November 3, 2025 |
Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update Exhibit 99.1 Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update · Recorded $51.7 million in net product sales of YUTREPIA™ as launch momentum continues · Achieved profitability in the first full quarter of YUTREPIA sales · More than 2,000 unique patient prescriptions and 1,500 patient starts to date · Company to host webcast today at 8:30 a.m. ET MORRIS |
|
| November 3, 2025 |
tree UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents tree UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission F |
|
| September 15, 2025 |
144 0001747589 XXXXXXXX LIVE 0001819576 LIQUIDIA CORPORATION 001-39724 419 Davis Drive, Suite 100 Morrisville, NC 27560 (919) 328-4400 RAMANDEEP SINGH Director Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 45524 1175042. |
|
| September 3, 2025 |
144 0001747589 XXXXXXXX LIVE 0001819576 Liquidia Corp 001-39724 419 Davis Drive, Suite 100 Morrisville NC 27560 919-328-4400 Singh Raman Director Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza, 8th Floor New York NY 10004 7500 220650. |
|
| September 2, 2025 |
144 0001832592 XXXXXXXX LIVE 0001819576 LIQUIDIA CORPORATION 001-39724 419 Davis Drive, Suite 100 Morrisville NC 27560 919-328-4400 SCOTT MOOMAW Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 70000 1937600. |
|
| August 29, 2025 |
144 0001494695 XXXXXXXX LIVE 0001819576 Liquidia Corp 001-39724 419 DAVIS DRIVE, SUITE 100 MORRISVILLE NC 27560 919. |
|
| August 28, 2025 |
144 0001747055 XXXXXXXX LIVE 0001819576 LIQUIDIA CORPORATION 001-39724 419 Davis Drive, Suite 100 Morrisville NC 27560 919-328-4400 JASON ADAIR Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 26057 729596. |
|
| August 28, 2025 |
144 0001935638 XXXXXXXX LIVE 0001819576 LIQUIDIA CORPORATION 001-39724 419 Davis Drive, Suite 100 Morrisville NC 27560 919-328-4400 RAJEEV SAGGAR Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 20000 560000. |
|
| August 28, 2025 |
144 0001494695 XXXXXXXX LIVE 0001819576 Liquidia Corp 001-39724 419 DAVIS DRIVE, SUITE 100 MORRISVILLE NC 27560 919. |
|
| August 12, 2025 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. PATHWAY TRIANGLE 1000 SCIENCE DRIVE MORRISVILLE, NORTH CAROLINA LEASE SUMMARY SHEET Execution Date: June 16, 2025 Tenant: Liquidia Technologies, Inc., a Delawar |
|
| August 12, 2025 |
tree UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents tree UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 12, 2025 |
Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update · YUTREPIA™ surpasses 900 unique patient prescriptions and 550 patient starts within 11 weeks after approval to treat PAH and PH-ILD · Positive interim data from ASCENT trial reinforces YUTREPIA’s tolerability and efficacy profile in PH-ILD with median improvement in six-minute walk distan |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File |
|
| June 24, 2025 |
Exhibit 99.1 Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™ MORRISVILLE, N.C., June 23, 2025 – Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced the receipt of an additional $50.0 million under its sixth amendment to its financing |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File |
|
| June 2, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File |
|
| June 2, 2025 |
Exhibit 99.1 Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD · YUTREPIA now available to be prescribed to patients via specialty pharmacies · FDA approved YUTREPIA on May 23, 2025 · Court denies United Therapeutics’ request for preliminary injunction and a temporary restraining order, clearing the path for full commercial |
|
| May 23, 2025 |
Exhibit 99.1 U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) · FDA’s approval of YUTREPIA paves the way for prescribers to add a new treatment option for patients with PAH and PH-ILD · YUTREPIA is designed to enhance deep-lung delivery with a |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File |
|
| May 12, 2025 |
Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics Exhibit 99.1 Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics · New litigation filed against Liquidia in U.S. District Court for the Middle District of North Carolina alleges infringement of UTHR’s ‘782 patent and seeks to enjoin Liquidia from commercializing YUTREPIA · ‘782 patent claims same general subject matter as UTHR’s invalidated ‘793 patent · Does not impact |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 8, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 (December 31, 2024) LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation |
|
| May 8, 2025 |
Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update Exhibit 99.1 Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update · Awaiting FDA action on YUTREPIA™ NDA with a PDUFA goal date of May 24, 2025 · District Court dismissed cross claim filed by United Therapeutics challenging PH-ILD amendment · Fully enrolled Cohort A of ASCENT study in patients with PH-ILD · Further strengthened financial position via acce |
|
| May 8, 2025 |
LIQUIDIA CORPORATION FINANCIAL STATEMENTS TABLE OF CONTENTS Exhibit 99.1 Item 8. Financial Statements and Supplementary Data LIQUIDIA CORPORATION FINANCIAL STATEMENTS TABLE OF CONTENTS Report of Independent Registered Public Accounting Firm (PCAOB ID: 238) F-2 Consolidated Balance Sheets as of December 31, 2024 and 2023 F-5 Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2024 and 2023 F-6 Consolidated Statement |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001 |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 5, 2025 |
District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia Exhibit 99.1 District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia · Court will not hear cross-claim that challenges the PH-ILD indication in the tentatively approved NDA for YUTREPIA · FDA can grant final approval of YUTREPIA after blocking regulatory exclusivity expires on May 23, 2025 MORRISVILLE, N.C., May 2, 2025 – Liquidia Corporation (NASDAQ: LQDA), a biopharmaceuti |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File N |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 25, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by R |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39724 LIQUIDIA CORPORATION (Exa |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 28, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 28, 2025 |
Exhibit 99.1 Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder · FDA sets PDUFA goal date of May 24, 2025 MORRISVILLE, N.C., March 28, 2025 – Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S. Foo |
|
| March 21, 2025 |
Liquidia Corporation 419 Davis Drive, Suite 100 Morrisville, NC 27560 March 21, 2025 Liquidia Corporation 419 Davis Drive, Suite 100 Morrisville, NC 27560 March 21, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| March 21, 2025 |
March 21, 2025 Roger Jeffs Chief Executive Officer Liquidia Corp 419 Davis Drive, Suite 100 Morrisville, NC 27560 Re: Liquidia Corp Registration Statement on Form S-3 Filed March 19, 2025 File No. |
|
| March 19, 2025 |
As filed with the Securities and Exchange Commission on March 19, 2025 As filed with the Securities and Exchange Commission on March 19, 2025 Registration No. |
|
| March 19, 2025 |
As filed with the Securities and Exchange Commission on March 19, 2025 As filed with the Securities and Exchange Commission on March 19, 2025 Registration Statement No. |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 19, 2025 |
Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update Exhibit 99.1 Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update · Targeting final FDA approval of YUTREPIA™ after expiration of regulatory exclusivity on May 23, 2025 · Advancing pipeline of inhaled treprostinil products in clinical studies · Strengthened financial position by up to $100 million via amendment to existing financing agreement with HealthCare |
|
| March 19, 2025 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Liquidia Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0. |
|
| March 19, 2025 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Liquidia Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0. |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39724 LIQUIDIA |
|
| March 19, 2025 |
Subsidiaries of Liquidia Corporation. EXHIBIT 21.1 Liquidia Technologies, Inc. Jurisdiction of incorporation: Delaware Name under which business conducted: Liquidia Technologies, Inc. Liquidia PAH, LLC Jurisdiction of organization: Delaware Name under which business conducted: Liquidia PAH, LLC |
|
| March 19, 2025 |
Exhibit 10.25 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. SIXTH AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT This SIXTH AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT (this “Amendment”), dated as of Ma |
|
| March 19, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) LIQUIDIA CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate- Offering Price(2) Fee Rate Amount of Registration Fee Newly Registered Securities Fees to Be Paid Equity Common Stock 457(c) 1,123,595 $ 14. |
|
| March 19, 2025 |
Exhibit 10.53 January 7, 2025 VIA: E-MAIL Michael Hunter Vice President, Manufacturing Operations Liquidia Technologies, Inc. 419 Davis Drive, Suite 100 Morrisville, North Carolina 27560 Re: Year 2, Launch Delay Dear Michael, Lonza Tampa LLC (‘‘Lonza’’) and Liquidia Technologies, Inc. (‘‘Liquidia’’) entered into an Amended and Restated Commercial Manufacturing Services and Supply Agreement, dated |
|
| March 19, 2025 |
As filed with the Securities and Exchange Commission on March 19, 2025 As filed with the Securities and Exchange Commission on March 19, 2025 Registration No. |
|
| March 18, 2025 |
Exhibit 99.1 Liquidia Corporation Strengthens Financial Position by Amending HealthCare Royalty Agreement to Incrementally Add Up to $100 Million MORRISVILLE, N.C., March 18, 2025 – Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that it has entered into a sixth amendment to its agreeme |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fil |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission |
|
| November 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission |
|
| November 26, 2024 |
EIGHTH AMENDMENT TO Lease Agreement Exhibit 99.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. EIGHTH AMENDMENT TO Lease Agreement THIS EIGHTH AMENDMENT TO LEASE AGREEMENT (this “Amendment”) is entered into effective as of the 22 day of November, 2024 (th |
|
| November 13, 2024 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. |
|
| November 13, 2024 |
Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.1 Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update · Received tentative approval from the FDA for YUTREPIA™ (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) · U.S. Supreme Court rejected final appeal of ‘793 patent decision, marking |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| November 13, 2024 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. |
|
| November 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission |
|
| November 12, 2024 |
LQDA / Liquidia Corporation / Manning Paul B - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 (Amendment No. 4)* Liquidia Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 53635D202 (CUSIP Number) Septe |
|
| November 8, 2024 |
LQDA / Liquidia Corporation / BlackRock, Inc. Passive Investment SC 13G 1 us53635d2027110824.txt us53635d2027110824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) LIQUIDIA CORP - (Name of Issuer) Common Stock - (Title of Class of Securities) 53635D202 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| October 18, 2024 |
LQDA / Liquidia Corporation / BlackRock, Inc. Passive Investment us53635d2027101824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) LIQUIDIA CORP - (Name of Issuer) Common Stock - (Title of Class of Securities) 53635D202 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| October 7, 2024 |
United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics’ Patent Exhibit 99.1 United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics’ Patent - U.S. Supreme Court denied United Therapeutics’ petition to appeal rulings that found all claims of U.S. Patent No. 10,716,793 (‘793 Patent) were invalid - Decisions that Liquidia does not infringe any valid claims of the three patents originally asserted by United Therapeutics are now |
|
| October 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 2, 2024 |
Exhibit 99.1 Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606) · Liquidia amends exclusive license to include key markets in Europe, Japan and elsewhere · Liquidia also obtains rights to Pharmosa’s next-generation nebulizers for use with L606 · Pharmosa to receive $3.5 million upfront and up to $157.75 million in additional development and |
|
| October 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fi |
|
| September 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission |
|
| September 12, 2024 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of September 10, 2024, by and among Liquidia Corporation, a Delaware corporation (the “Company”) and the purchasers identified on Schedule A hereto (each, a “Purchaser” and collectively, the “Purchasers”) and such other Persons, if any, from time to time, that become a party hereto as holder |
|
| September 12, 2024 |
Exhibit 1.1 Execution Version 6,460,674 Shares Liquidia Corporation UNDERWRITING AGREEMENT September 11, 2024 BofA Securities, Inc. As Representative of the several Underwriters c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 Ladies and Gentlemen: Introductory. Liquidia Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the se |
|
| September 12, 2024 |
LQDA / Liquidia Corporation / Caligan Partners LP - LIQUIDIA CORP Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 4)* Liquidia Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 53635D202 (CUSIP Number) Dav |
|
| September 12, 2024 |
Exhibit 10.3 Execution Version CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. FIFTH AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT This FIFTH AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT (this “ |
|
| September 12, 2024 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission |
|
| September 12, 2024 |
Exhibit 10.1 COMMON STOCK PURCHASE AGREEMENT COMMON STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of September 10, 2024, by and among Liquidia Corporation, a Delaware corporation, with headquarters located at 419 Davis Drive, Suite 100, Morrisville, NC 27560 (the “Company”) and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, |
|
| September 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission |
|
| September 11, 2024 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(4) Registration No. 333-276244 PROSPECTUS SUPPLEMENT (To prospectus dated December 28, 2023) 6,460,674 Shares Common Stock We are offering 6,460,674 shares of common stock. Our common stock is listed on The Nasdaq Capital Market under the symbol “LQDA.” The last reported sale price of our common stock on The Nasdaq Capital Market on September 10, |
|
| September 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission |
|
| September 11, 2024 |
Exhibit 99.1 Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement MORRISVILLE, N.C., September 11, 2024 – Liquidia Corporation (NASDAQ: LQDA) (the “Company” or “Liquidia”), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, |
|
| September 11, 2024 |
Free Writing Prospectus filed pursuant to Rule 433 Registration Statement No. 333-276244 Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement MORRISVILLE, N.C., September 11, 2024 – Liquidia Corporation (NASDAQ: LQDA) (the “Company” or “Liquidia”), a biopharmaceutical company devel |
|
| September 4, 2024 |
LQDA / Liquidia Corporation / Caligan Partners LP - LIQUIDIA CORPORATION Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 3)* Liquidia Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 53635D202 (CUSIP Number) Dav |
|
| August 22, 2024 |
Exhibit 99.1 Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA™ (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD MORRISVILLE, N.C., August 22,2024 - Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it has filed litig |
|
| August 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 19, 2024 |
Exhibit 99.1 U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) ● FDA confirmed that the amendment to add PH-ILD to the YUTREPIA NDA was proper and that application otherwise meets the requirements for approval under the Federal Food, D |
|
| August 7, 2024 |
Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update MORRISVILLE, N.C., August 7, 2024 - Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the second quarter ended June 30, 2024. The company will host a webcast |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001- |
|
| July 2, 2024 |
Liquidia Corporation 419 Davis Drive, Suite 100 Morrisville, NC 27560 July 2, 2024 Liquidia Corporation 419 Davis Drive, Suite 100 Morrisville, NC 27560 July 2, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| July 1, 2024 |
July 1, 2024 Roger A. Jeffs, Ph.D. Chief Executive Officer Liquidia Corporation 419 Davis Drive, Suite 100 Morrisville, North Carolina 27560 Re: Liquidia Corporation Registration Statement on Form S-3 Filed June 27, 2024 File No. 333-280540 Dear Roger A. Jeffs Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 r |
|
| June 27, 2024 |
As filed with the Securities and Exchange Commission on June 27, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 27, 2024 Registration Statement No. |
|
| June 27, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) LIQUIDIA CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate- Offering Price(2) Fee Rate Amount of Registration Fee Newly Registered Securities Fees to Be Paid Equity Common Stock 457(c) 7,322,197 $ 12. |
|
| June 21, 2024 |
Exhibit 3.1 CERTIFICATE OF SECOND AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF LIQUIDIA CORPORATION Liquidia Corporation, a corporation duly organized and validly existing under and by virtue of the General Corporation Law of the State of Delaware (the “Company”), does hereby certify as follows: FIRST: The Certificate of Incorporation, as amended, of the Company (the “Certificate of Incorporat |
|
| June 21, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File |
|
| June 3, 2024 |
Exhibit 99.1 District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch · On May 31, Judge Andrews denied United Therapeutics’ motion for a preliminary injunction to block the launch of YUTREPIA in the PH-ILD indication · Ruling reinforces the clear path for FDA to issue final decision on amended NDA for YUTREPIA to treat both PAH and PH-ILD MORRISVILL |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File |
|
| May 14, 2024 |
Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.1 Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update MORRISVILLE, N.C., May 13, 2024 – Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the first quarter ended March 31, 2024. The company will host a webcast at 8:30 a.m. ET on May 14, 2024 to discuss the financial results and provide a corporate update. Dr. Roger Jeffs |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File |
|
| May 14, 2024 |
Liquidia Corporation Amended and Restated Executive Severance and Change in Control Plan Exhibit 10.1 Liquidia Corporation Amended and Restated Executive Severance and Change in Control Plan Table of Contents Page ARTICLE I Statement of Purpose and Effective Date 1 1.01 Purpose 1 1.02 Effective Date 1 ARTICLE II Definitions 1 ARTICLE III Participation and Eligibility for Benefits 8 3.01 Eligibility 8 3.02 Participation 8 3.03 Eligibility for Benefits 8 ARTICLE IV Obligations of the Em |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001 |
|
| April 29, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by R |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39724 LIQUIDIA CORPORATION (Exa |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 12, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by R |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File |
|
| April 1, 2024 |
Exhibit 99.1 Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder · On March 28, Judge Andrews removed the injunction issued in the Original Hatch Waxman Litigation · On March 29, Judge Bates denied United Therapeutics’ motion for temporary restraining order and preliminary injunction in separate litigation filed b |
|
| March 13, 2024 |
Exhibit 10.47 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. AMENDED AND RESTATED COMMERCIAL MANUFACTURING SERVICES AND SUPPLY AGREEMENT This Amended and Restated Commercial Manufacturing Services and Supply Agreement (t |
|
| March 13, 2024 |
Exhibit 10.20 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. EXECUTION VERSION THIRD AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT This THIRD AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT (this “Amendment |
|
| March 13, 2024 |
Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update Exhibit 99.1 Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update - Preparing to launch YUTREPIA™ (treprostinil) inhalation powder upon final FDA approval - Federal Circuit rejected request by United Therapeutics for rehearing of earlier decision finding ‘793 Patent invalid - Advancing industry leading portfolio for inhaled treprostinil with YUTREPIA and sust |
|
| March 13, 2024 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Liquidia Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0. |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39724 LIQUIDIA |
|
| March 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 13, 2024 |
As filed with the Securities and Exchange Commission on March 13, 2024 As filed with the Securities and Exchange Commission on March 13, 2024 Registration No. |
|
| March 13, 2024 |
Exhibit 10.4 LIQUIDIA CORPORATION 2020 LONG-TERM INCENTIVE PLAN TABLE OF CONTENTS 1. History; Existence of the Plan1 2. Purposes of the Plan1 3. Terminology1 4. Administration1 (a) Administration of the Plan1 (b) Powers of the Administrator1 (c) Delegation of Administrative Authority3 (d) Non-Uniform Determinations3 (e) Limited Liability; Advisors3 (f) Indemnification3 (g) Effect of Admi |
|
| March 13, 2024 |
Exhibit 10.49 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. Execution Version LICENSE AGREEMENT dated as of June 28, 2023 by and between Pharmosa Biopharm Inc. and Liquidia Technologies, Inc. Table of Contents Page ARTI |
|
| March 13, 2024 |
Exhibit 10.19 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. SECOND AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT This SECOND AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT, dated as of June 28, 2023 (this |
|
| March 13, 2024 |
Exhibit 10.7 LIQUIDIA CORPORATION RESTRICTED STOCK UNITS NOTICE (Performance Based) UNDER THE LIQUIDIA CORPORATION 2020 LONG-TERM INCENTIVE PLAN Name of Grantee: This Notice evidences the award of performance-based restricted stock units (each, an “RSU,” and collectively, the “RSUs”) of LIQUIDIA Corporation, a Delaware corporation (the “Company”), that have been granted to you pursuant to the Liqu |
|
| March 13, 2024 |
Description of Securities of the Company. Exhibit 4.7 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The only class of securities of Liquidia Corporation, a Delaware corporation (the “Company”), registered under Section 12 of the Securities Exchange Act of 1934, as amended, is common stock, par value $0.001 per share (“common stock”). The following description of the Com |
|
| March 13, 2024 |
Exhibit 10.50 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. Execution Version ASSET Transfer AGREEMENT This ASSET TRANSFER AGREEMENT (this “Agreement”) is made and entered as of June 28, 2023 (“Effective Date”) by and b |
|
| March 13, 2024 |
Exhibit 14.1 CODE OF CONDUCT As amended on March 8, 2022 TABLE OF CONTENTS INTRODUCTION1 MISSION STATEMENT2 OUR PURPOSE2 OUR PRINCIPLES2 REPORTING VIOLATIONS3 COMPLIANCE3 NO RETALIATION3 MORAL STANDARDS4 CONFLICT OF INTEREST4 Gifts & Entertainment5 Bribes, Kickbacks & Unlawful Payments6 Foreign Corrupt Practices Act7 Anti-Money Laundering 8 Company Assets 8 Competing Outside Employment & Business |
|
| March 13, 2024 |
Exhibit 10.9 Grant No.: LIQUIDIA CORPORATION NONSTATUTORY STOCK OPTION NOTICE This Notice evidences the award of nonstatutory stock options (each, an “Option” or collectively, the “Options”) that have been granted to you, [NAME], subject to and conditioned upon your agreement to the terms of the attached Nonstatutory Stock Option Agreement (the “Agreement”). The Options entitle you to purchase sha |
|
| March 13, 2024 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Liquidia Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0. |
|
| March 13, 2024 |
Subsidiaries of Liquidia Corporation. EXHIBIT 21.1 Liquidia Technologies, Inc. Jurisdiction of incorporation: Delaware Name under which business conducted: Liquidia Technologies, Inc. Liquidia PAH, LLC Jurisdiction of organization: Delaware Name under which business conducted: Liquidia PAH, LLC |
|
| March 13, 2024 |
Exhibit 10.6 LIQUIDIA CORPORATION RESTRICTED STOCK UNITS NOTICE UNDER THE LIQUIDIA CORPORATION 2020 LONG-TERM INCENTIVE PLAN Name of Grantee: This Notice evidences the award of restricted stock units (each, an “RSU,” and collectively, the “RSUs”) of LIQUIDIA Corporation, a Delaware corporation (the “Company”), that have been granted to you pursuant to the Liquidia Corporation 2020 Long-Term Incent |
|
| March 13, 2024 |
Exhibit 10.8 Grant No.: LIQUIDIA CORPORATION INCENTIVE STOCK OPTION NOTICE This Notice evidences the award of stock options (each, an “Option” or collectively, the “Options”) that have been granted to you, [NAME], subject to and conditioned upon your agreement to the terms of the attached Incentive Stock Option Agreement (the “Agreement”). The Options entitle you to purchase shares of common stock |
|
| March 13, 2024 |
Supply Agreement, dated May 22, 2023, by and between Liquidia Technologies, Inc. and Plastiape SpA. Exhibit 10.51 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. Supply Agreement (“Agreement”) Parties. 1.Liquidia Technologies, Inc., 419 Davis Dr., Suite 100, Morrisville, NC 27560 United States，email supplychain@liquidia |
|
| March 13, 2024 |
As filed with the Securities and Exchange Commission on March 13, 2024 As filed with the Securities and Exchange Commission on March 13, 2024 Registration No. |
|
| February 14, 2024 |
LQDA / Liquidia Corporation / Manning Paul B - SC 13G/A Passive Investment SC 13G/A 1 tm245987d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 (Amendment No. 3)* Liquidia Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of S |
|
| February 7, 2024 |
LQDA / Liquidia Corporation / BlackRock Inc. Passive Investment SC 13G/A 1 us53635d2027020724.txt us53635d2027020724.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) LIQUIDIA CORP - (Name of Issuer) Common Stock - (Title of Class of Securities) 53635D202 - (CUSIP Number) January 31, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| January 31, 2024 |
LQDA / Liquidia Corporation / BlackRock Inc. Passive Investment SC 13G 1 us53635d2027013124.txt us53635d2027013124.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) LIQUIDIA CORP - (Name of Issuer) Common Stock - (Title of Class of Securities) 53635D202 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| January 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission F |
|
| January 25, 2024 |
Exhibit 99.1 Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder MORRISVILLE, N.C., January 25, 2024 - Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) provided an update on its review of the New Drug Application (NDA) for YUTREPIA™ (treprostinil) inhalation powder to treat pul |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission F |
|
| January 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission F |
|
| January 19, 2024 |
Exhibit 99.1 CONFIDENTIAL INFORMATION Liquidia Corporation Announces Updates to Operations Leadership MORRISVILLE, N.C., January 19, 2024 – Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today updates and promotions to its operations leadership in advance of the potential approval and launch of YUTREPIA™ (treprostinil) inhalation powder. Michael Kaseta, Chief Financial Off |
|
| January 16, 2024 |
LQDA / Liquidia Corporation / Legend Aggregator, LP - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Liquidia Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 53635D202 (CUSIP Number) January 4, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| January 16, 2024 |
EX-99.A 2 d590854dex99a.htm EX-99.A Exhibit A Joint Filing Agreement The undersigned hereby agree to the joint filing on behalf of each of them of the Statement on Schedule 13G with respect to the Common Stock of Liquidia Corporation, and any further amendments to such statement on Schedule 13G executed by each of them pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Se |
|
| January 8, 2024 |
Exhibit 10.1 Execution Version * Certain terms of this Exhibit 10.1 have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K as they are both not material and of the type that the registrant treats as private or confidential. FOURTH AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT This FOURTH AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT (this “Amendment”), dated as of Janu |
|
| January 8, 2024 |
Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD Exhibit 99.1 Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD January 5, 2024 • Enrolled first PH-ILD patient in the open-label ASCENT study of YUTREPIA • Confirmed with FDA that a single pivotal efficacy trial with L606 will support PAH and PH-ILD indications MORRISVILLE, N.C., January 5, 2024 (GLOBE NEWSWIRE) - Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) p |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 8, 2024 |
Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims Exhibit 99.2 Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims January 8, 2024 • Seeks dismissal of all claims related to ‘793 patent based on prior findings of invalidity which have been affirmed by the Federal Circuit • Requests declaration that ’327 patent is not infringed, is invalid and is unenforceable • Files counterclaims asserting United Therapeuti |
|
| January 8, 2024 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of January 4, 2024, by and among Liquidia Corporation, a Delaware corporation (the “Company”) and the purchasers identified on Schedule A hereto (each, a “Purchaser” and collectively, the “Purchasers”) and such other Persons, if any, from time to time, that become a party hereto as holders o |
|
| January 8, 2024 |
Exhibit 10.2 COMMON STOCK PURCHASE AGREEMENT COMMON STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of January 4, 2024, by and among Liquidia Corporation, a Delaware corporation, with headquarters located at 419 Davis Drive, Suite 100, Morrisville, NC 27560 (the “Company”) and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, th |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 5, 2024 |
Liquidia Corporation Announces $100 Million in New Financings Exhibit 99.1 Liquidia Corporation Announces $100 Million in New Financings - Agreed to $75.0 million sale of common stock to fund affiliated with Patient Square Capital in a private placement - Additional advance of $25.0 million from HealthCare Royalty under current financing agreement MORRISVILLE, N.C., January 4, 2024 - Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced tod |
|
| December 29, 2023 |
Liquidia Corporation 419 Davis Drive, Suite 100 Morrisville, NC 27560 December 29, 2023 Liquidia Corporation 419 Davis Drive, Suite 100 Morrisville, NC 27560 December 29, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| December 28, 2023 |
United States securities and exchange commission logo December 28, 2023 Russell Schundler General Counsel Liquidia Corp 419 Davis Drive, Suite 100 Morrisville, North Carolina 27560 Re: Liquidia Corp Registration Statement on Form S-3 Filed December 22, 2023 File No. |
|
| December 28, 2023 |
As filed with the Securities and Exchange Commission on December 28, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 28, 2023 Registration Statement No. |
|
| December 22, 2023 |
Exhibit 4.8 LIQUIDA CORPORATION and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Inappli |
|
| December 22, 2023 |
Form of Subordinated Indenture* Exhibit 4.9 LIQUIDA CORPORATION and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) I |
|
| December 22, 2023 |
As filed with the Securities and Exchange Commission on December 22, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 22, 2023 Registration Statement No. |
|
| December 22, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) LIQUIDIA CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, $0. |
|
| December 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission |
|
| December 20, 2023 |
Exhibit 99.1 U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent) - Liquidia will pursue final FDA approval for YUTREPIA™ (treprostinil) inhalation - Liquidia will immediately request that District Court set aside injunction tied to ‘793 patent MORRISVILLE, N.C., December 20, 2023 - Liquidia Corporation (NASDAQ: LQDA |
|
| December 14, 2023 |
Exhibit 1.1 Execution Version 3,491,620 Shares Liquidia Corporation UNDERWRITING AGREEMENT December 12, 2023 BofA Securities, Inc. As Representative of the several Underwriters c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 Ladies and Gentlemen: Introductory. Liquidia Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters nam |
|
| December 14, 2023 |
LQDA / Liquidia Corp / Caligan Partners LP - LIQUIDIA CORPORATION Activist Investment SC 13D/A 1 p23-2975sc13da.htm LIQUIDIA CORPORATION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 2)* Liquidia Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title o |
|
| December 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 (December 12, 2023) LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorpo |
|
| December 14, 2023 |
Exhibit 10.1 COMMON STOCK PURCHASE AGREEMENT COMMON STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of December 12, 2023, by and among Liquidia Corporation, a Delaware corporation, with headquarters located at 419 Davis Drive, Suite 100, Morrisville, NC 27560 (the “Company”) and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, |
|
| December 12, 2023 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(2) (Form Type) LIQUIDIA CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, $0. |
|
| December 12, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission |
|
| December 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission |
|
| December 12, 2023 |
Liquidia Announces Pricing of Public Offering of Common Stock Exhibit 99.1 Liquidia Announces Pricing of Public Offering of Common Stock RESEARCH TRIANGLE PARK, N.C., December 12, 2023 - Liquidia Corporation (NASDAQ: LQDA) announced today that it has priced an underwritten public offering of 3,491,620 shares of common stock at a public offering price of $7.16 for total gross proceeds of approximately $25.0 million, before deducting underwriting discounts and |
|
| December 12, 2023 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(2) Registration No. 333-251394 PROSPECTUS SUPPLEMENT (To prospectus dated December 23, 2020) 3,491,620 Shares Common Stock We are offering 3,491,620 shares of common stock. Our common stock is listed on The Nasdaq Capital Market under the symbol “LQDA.” The last reported sale price of our common stock on The Nasdaq Capital Market on December 11, 20 |
|
| December 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission F |
|
| November 7, 2023 |
Exhibit 10.1 liquidia corporation Policy for RECOVERY OF ERRONEOUSLY AWARDED Incentive Compensation (Adopted: November 2, 2023) 1. INTRODUCTION Liquidia Corporation, a Delaware corporation (the “Company”) is adopting this policy (this “Policy”) to provide for the Company’s recovery of certain Incentive Compensation (as defined below) erroneously awarded to Affected Officers (as defined below) unde |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| November 7, 2023 |
Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update Exhibit 99.1 Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update · Oral arguments in appeal of ‘793 PTAB decision set for December 4, 2023 · PDUFA goal date to add PH-ILD indication to YUTREPIA label is January 24, 2024 · Hired sales force in preparation of potential positive legal and regulatory outcomes MORRISVILLE, N.C., November 7, 2023 - Liquidia Co |
|
| September 25, 2023 |
FDA Accepts Submission to Add PH-ILD to YUTREPIA™ Label Exhibit 99.1 FDA Accepts Submission to Add PH-ILD to YUTREPIA™ Label · Sets PDUFA goal date of January 24, 2024 · If approved, YUTREPIA would be indicated for treatment of both PAH and PH-ILD MORRISVILLE, N.C., September 25, 2023 - Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) accepted for review the Company’s amendment to the te |
|
| September 25, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission |
|
| September 6, 2023 |
Exhibit 99.1 United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office · Asserts ‘793 patent in new litigation filed under Hatch-Waxman Act in response to Liquidia’s amendment to its NDA to add PH-ILD to YUTREPIA™ label · Litigation is tied to same ‘793 patent previously ruled invalid by Patent Trial and Appeal Board (PTA |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 10, 2023 |
Exhibit 10.4 ASSET Transfer AGREEMENT This ASSET TRANSFER AGREEMENT (this “Agreement”) is made and entered as of June 28, 2023 (“Effective Date”) by and between Pharmosa Biopharm Inc., a corporation incorporated under the laws of Taiwan having a place of business at 3F.-3, No. 66, Sanchong Road, Nangang District, Taipei City 11502, Taiwan (“Seller”), and Liquidia Technologies, Inc., a corporation |
|
| August 10, 2023 |
Supply Agreement, dated May 22, 2023, by and between Liquidia Technologies, Inc. and Plastiape SpA. Exhibit 10.5 Supply Agreement (“Agreement”) Parties. 1.Liquidia Technologies, Inc., 419 Davis Dr., Suite 100, Morrisville, NC 27560 United States，email [email protected] ( “Liquidia”). 2.Plastiape SpA of 23875 Osnago (Lecco) - Via 1 Maggio, 8, Italy facsimile +39 039 587805 email [email protected] (“Plastiape” and, collectively with Liquidia, the “Parties” and each a “Party”). Int |
|
| August 10, 2023 |
Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate Update Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate Update MORRISVILLE, N.C., August 10, 2023 - Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the second quarter ended June 30, 2023. The Company will host a webcast at 8:30 a.m. ET to discuss the financial results and provide a corporate update. D |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001- |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 10, 2023 |
Exhibit 10.3 LICENSE AGREEMENT dated as of June 28, 2023 by and between Pharmosa Biopharm Inc. and Liquidia Technologies, Inc. Table of Contents Page ARTICLE 1 Definitions1 ARTICLE 2 Licenses AND OTHER RIGHTS10 2.1 Grant of License to Company10 2.2 Grant of Sublicense by Company10 2.3 Licensor Technology Transfer11 2.4 Regulatory Technology Transfer and Existing Third Party Agreements11 2.5 |
|
| August 10, 2023 |
Exhibit 10.1 SECOND AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT This SECOND AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT, dated as of June 28, 2023 (this “Amendment”), is entered into by and between Liquidia Technologies, Inc., a Delaware corporation (the “Company”), and Healthcare Royalty Partners IV, L.P., a Delaware limited liability partnership, as the sole Investor and Inve |
|
| August 10, 2023 |
Exhibit 10.2 THIRD AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT This THIRD AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT (this “Amendment”), dated as of July 27, 2023 (the “Amendment Effective Date”), is entered into by and between Liquidia Technologies, Inc., a Delaware corporation (the “Company”), and Healthcare Royalty Partners IV, L.P., a Delaware limited liability partnership |
|
| August 10, 2023 |
Exhibit 10.6 AMENDED AND RESTATED COMMERCIAL MANUFACTURING SERVICES AND SUPPLY AGREEMENT This Amended and Restated Commercial Manufacturing Services and Supply Agreement (the “Agreement”) is made and entered into as of July 13, 2023 (“Effective Date”), by and between Liquidia Technologies, Inc., with a principal place of business at 419 Davis Drive, Suite 100, Morrisville NC 27560 (“Customer”), an |
|
| August 10, 2023 |
Exhibit 3.1 ACTIVE\600390586.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF LIQUIDIA CORPORATION Liquidia Corporation, a corporation duly organized and validly existing under and by virtue of the General Corporation Law of the State of Delaware (the “Company”), does hereby certify as follows: FIRST: The Certificate of Incorporation of the Company is hereby amended by deleting th |
|
| July 27, 2023 |
Exhibit 99.1 Confidential Information Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA™ (treprostinil) Inhalation Powder Confidential Information - No new clinical data is required to add PH-ILD indication as per FDA correspondence - Recertified that YUTREPIA does not infringe any valid patents listed in the Orange Book for Tyvaso - Preparing for potenti |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File |
|
| July 24, 2023 |
U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation Exhibit 99.1 U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation - Infringement case now only focused on ‘793 patent, previously found to be invalid by PTAB in IPR - Federal Circuit expected to hear appeal of PTAB decision in late 4th quarter 2023 to early 2024 - If PTAB decision affirmed, Liquidia will request final regulatory approval for YUTREPIA™ (treprostinil) inhalat |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File |
|
| July 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File |
|
| June 28, 2023 |
Exhibit 99.1 Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North America · Liquidia exclusively licenses North American rights to L606, an inhaled formulation of treprostinil administered twice-daily with a short duration, next-generation nebulizer · Liquidia funds $10 million upfront payment from finance agreement with Heal |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File |
|
| June 8, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File |
|
| May 8, 2023 |
Exhibit 10.1 FOURTH AMENDMENT TO PROMOTION AGREEMENT This Fourth Amendment to Promotion Agreement (this “Fourth Amendment”), is entered into as of March 10, 2023 (the “Fourth Amendment Effective Date”) by and between Sandoz Inc. (“Sandoz”) and Liquidia PAH, LLC, formerly known as RareGen, LLC (“RareGen”). BACKGROUND WHEREAS, Sandoz and RareGen are parties to that certain Promotion Agreement, dated |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001 |
|
| May 8, 2023 |
Exhibit 10.3 FIRST AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT This FIRST AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT, dated as of April 17, 2023 (this “Amendment”), is entered into by and among Liquidia Technologies, Inc., a Delaware corporation (the “Company”), Healthcare Royalty Partners IV, L.P., a Delaware limited liability partnership (the “Investor”), and HCR Collateral |
|
| May 8, 2023 |
Exhibit 10.2 RESEARCH LICENSE AGREEMENT This Research License Agreement (the “Agreement”) is entered into as of March 31, 2023 (the “Effective Date”) by and between Liquidia Technologies, Inc., a Delaware corporation, having its principal place of business at 419 Davis Dr., Suite 100, Morrisville, NC 27560 (“Liquidia”), and Glaxo Group Limited, a company organized and existing under the laws of En |
|
| May 5, 2023 |
LQDA / Liquidia Corp / BlackRock Inc. Passive Investment us53635d2027050423.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) LIQUIDIA CORP - (Name of Issuer) Common Stock - (Title of Class of Securities) 53635D202 - (CUSIP Number) April 30, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| May 4, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 4, 2023 |
LIQUIDIA FIRST QUARTER 2023 FINANCIAL RESULTS AND CORPORATE UPDATE CONFERENCE CALL Exhibit 99.2 LIQUIDIA FIRST QUARTER 2023 FINANCIAL RESULTS AND CORPORATE UPDATE CONFERENCE CALL Thursday May 4, 2023 at 8:30 AM ET OPERATOR: Good morning and welcome everyone to the Liquidia Corporation First Quarter 2023 Financial Results and Corporate Update conference call. My name is Lisa and I will be your conference operator today. Currently, all participants are in a listen-only mode. Follo |
|
| May 4, 2023 |
Liquidia Corporation Reports First Quarter 2023 Financial Results and Provides Corporate Update Exhibit 99.1 Liquidia Corporation Reports First Quarter 2023 Financial Results and Provides Corporate Update MORRISVILLE, N.C., May 4, 2023 - Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the first quarter ended March 31, 2023. The Company will host a webcast at 8:30 a.m. ET to discuss the financial results and provide a corporate update. Roger |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 28, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39724 LIQUIDIA CORPORATION |
|
| April 17, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 3, 2023 |
Liquidia and GSK Restructure License to PRINT Technology for Inhaled Applications Exhibit 99.1 Liquidia and GSK Restructure License to PRINT Technology for Inhaled Applications - New agreement supersedes the collaboration agreement entered in 2012 - GSK retains non-exclusive right to use PRINT for pre-clinical research for inhaled delivery - Liquidia can apply PRINT to any inhaled application other than identified GSK proprietary molecules MORRISVILLE, N.C., April 3, 2023 - Liq |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 20, 2023 |
Subsidiaries of Liquidia Corporation. EXHIBIT 21.1 Liquidia Technologies, Inc. Jurisdiction of incorporation: Delaware Name under which business conducted: Liquidia Technologies, Inc. Liquidia PAH, LLC Jurisdiction of organization: Delaware Name under which business conducted: Liquidia PAH, LLC |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39724 LIQUIDIA |
|
| March 20, 2023 |
As filed with the Securities and Exchange Commission on March 20, 2023 As filed with the Securities and Exchange Commission on March 20, 2023 Registration No. |
|
| March 20, 2023 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. |
|
| March 20, 2023 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. |
|
| March 20, 2023 |
As filed with the Securities and Exchange Commission on March 20, 2023 As filed with the Securities and Exchange Commission on March 20, 2023 Registration No. |
|
| March 20, 2023 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Liquidia Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0. |
|
| March 20, 2023 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. |
|
| March 20, 2023 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Liquidia Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0. |
|
| March 16, 2023 |
Liquidia Corporation Reports Full Year 2022 Financial Results and Provides Corporate Update Exhibit 99.1 Liquidia Corporation Reports Full Year 2022 Financial Results and Provides Corporate Update - Clarified path to potential launch YUTREPIA upon resolution of litigation in late-2023 to mid-2024 - Fortified financial position through 2024 - Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., March 16, 2023 - Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fil |
|
| February 14, 2023 |
LQDA / Liquidia Technologies Inc / Manning Paul B - AMENDMENT TO FORM SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 (Amendment No. 2)* Liquidia Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 53635D202 (CUSIP Number) Decem |
